by Harriet Boyd | Jan 9, 2020 | Press Releases, Welcome
Isogenica announces multimillion-pound agreement with recently nasdaq listed BioNTech SE Isogenica multi-target, multi-year collaboration and license agreement with BioNTech SE Isogenica has entered into a multi-target, multi-year partnership with BioNTech. The... by Harriet Boyd | Oct 15, 2019 | Press Releases, Welcome
Isogenica appoints Dr Bjӧrn Cochlovius to the Board of Directors Dr Cochlovius joins Isogenica as a non-executive director replacing Dr Gӧran Forsberg, who stepped down from the Board on October 11, 2019. Dr Forsberg has served as a non-executive director since... by Harriet Boyd | Sep 19, 2019 | Press Releases, Welcome
Isogenica appoints Dr David Mead as Director of Business Development Isogenica today announced the appointment of Dr David Mead as Director of Business Development effective immediately. Dr Mead was previously Business Development Director at Albumedix where he was... by Harriet Boyd | Jan 8, 2019 | Press Releases, Welcome
Isogenica expands collaboration with Aro Biotherapeutics Isogenica today announced an expansion of the collaboration and license agreement signed with Aro Biotherapeutics in June 2018. Under the expanded agreement, Isogenica will use its CIS Display platform to help... by Harriet Boyd | Sep 3, 2018 | Press Releases, Welcome
Isogenica appoints Dr Emma Sceats as Chief Executive Officer Isogenica Ltd, a leader in the design and construction of diverse, fully synthetic, antibody libraries for biopharmaceutical discovery, today announced that Dr Emma Sceats has been appointed Chief Executive... by Harriet Boyd | Apr 18, 2018 | Press Releases, Welcome
Fusion Pharmaceuticals Licenses Isogenica’s CIS Display Technology Fusion Pharmaceuticals Licenses Isogenica’s CIS Display Technology. Technology will be used to progress Fusion’s pipeline of alpha therapeutics for the treatment of cancers. Isogenica Ltd and Fusion...